Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 9/20 | 0.58 |
| ▸ | DRD4 | P21917 | 9/20 | 0.58 |
| ▸ | DRD3 | P35462 | 9/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7166172 | 0.99 | SLC6A1 (0.58) | SLC6A1DRD2DRD4DRD3CHRM1 | |
| SCHEMBL5500223 | 0.97 | CHRM1 (0.61) | SLC6A1DRD2DRD4DRD3CHRM1 | |
| Hydrochloric Acid SCHEMBL6962296 | 0.96 | CHRM1 (0.60) | SLC6A1DRD2DRD4DRD3CHRM1 | |
| SCHEMBL5495263 | 0.90 | DRD2 (0.55) | SLC6A1DRD2DRD4DRD3CHRM1 | |
| Hydrochloric Acid SCHEMBL7167859 | 0.89 | MEN1 (0.55) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL5494495 | 0.88 | DRD2 (0.57) | DRD2DRD4DRD3CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL6963930 | 0.87 | DRD2 (0.56) | DRD2DRD4DRD3CHRM1CHRM2 | |
| SCHEMBL7605625 | 0.85 | SLC6A1 (0.81) | SLC6A1 | |
| SCHEMBL5501217 | 0.85 | DRD2 (0.51) | SLC6A1DRD2DRD4DRD3CHRM1 | |
| Hydrochloric Acid SCHEMBL8187342 | 0.84 | SLC6A1 (0.80) | SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569849-B1 | N-Substituted azaheterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | claimed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| JP-2001501629-A | — | — | 2001-02-06 | — | — | JP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-0934306-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | claimed |
| WO-1998015546-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | claimed |
| US-20070066570-A1 | Methods for treating sleep disorders | HYPNION, INC. | 2007-03-22 | — | — | US | disclosed |
| WO-2004112705-A2 | METHODS FOR TREATING SLEEP DISORDERS | HYPNION, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066570-A1 | Methods for treating sleep disorders | HCRTR2, HNMT, HCRTR1 | SLC6A1 100/4885DRD2 366/4885DRD4 594/4885 |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | SLC6A1 3399/4885DRD2 2668/4885DRD4 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.